Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

Alice L. Yu; Andrew L. Gilman; M. Fevzi Özkaynak; Wendy B. London; Susan G. Kreissman; Helen X. Chen; Malcolm A. Smith; Barry Anderson; Judith G. Villablanca; Katherine K. Matthay; Hiro Shimada; Stephan A. Grupp; Robert C. Seeger; C. Patrick Reynolds; Allen Buxton; Ralph A. Reisfeld; S. D. Gillies; Susan L. Cohn; John M. Maris; Paul M. Sondel

doi:10.1056/nejmoa0911123

Key Points

The aim is to evaluate the effectiveness of anti-GD2 antibody therapy combined with GM-CSF and interleukin-2 in treating high-risk neuroblastoma.
Immunotherapy involving anti-GD2 antibody ch14.18, GM-CSF, and interleukin-2.
Comparison with standard therapy.
ClinicalTrials.gov number: NCT00026312.
Immunotherapy was associated with significantly improved outcomes compared to standard therapy.

Implication

Shows improved outcomes in high-risk neuroblastoma, highlighting the effectiveness of immunotherapy.

Abstract

Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma. (Funded by the National Institutes of Health and the Food and Drug Administration; ClinicalTrials.gov number, NCT00026312.)

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yu et al. (2010) studied this question.

synapsesocial.com/papers/69dd6070ae7c4d5b29100f12 https://doi.org/10.1056/nejmoa0911123

View Full Paper

Ask AI

Bookmark

Share

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from New England Journal of Medicine

Keep reading

More related papers

More from New England Journal of Medicine